



Washington State Health Care Authority
Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

December 6, 2024

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective January 1, 2025:

| Insomnia Drugs reviewed 12/13/2023 | | Agency Coverage | |
|---|---------------------------------|-----------------------------|-----|
| Ingredient Name | Label Name of Preferred Product | L&I | UMP |
| eszopiclone | eszopiclone tablet | No | Yes |
| ramelteon | ramelteon tablet | Yes | Yes |
| zaleplon | zaleplon capsule | Yes, acute use only | Yes |
| zolpidem tartrate | zolpidem tartrate sublingual | PA required, acute use only | Yes |
| | zolpidem tartrate tablet | Yes, acute use only | Yes |
| | zolpidem tartrate ER | No | Yes |
| The effect of this recommendation is to make eszopiclone preferred on the WA PDL. | | | |

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (360) 725-1188 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Donna Sullivan
Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority